Leveraging RNA-Seq for a robust, accurate measure of HLA calling for endpoints in clinical trials

Get in Touch

Our Locations

Victor Weigman, Ph.D.

Leveraging RNA-Seq for a robust, accurate measure of HLA calling for endpoints in clinical trials

Presentation from The 2017 Immuno-Oncology Summit In Boston, MA

Presented at The Immuno-Oncology Summit in August, 2017, this presentation highlights HLA typing in immunotherapy trials, including advantages and difficulties as well as types of HLA typing. This presentation also provides the benefits of HLAProfiler.

Author:
Victor Weigman, Ph.D., Director, Translational Genomics

Related Services & Solutions

Related Thought Leaders Insights

Scientific Poster

Robust performance of single-cell multiomic analysis (CITE-Seq) demonstrated across multiple locations, replicates, and donors on challenging cryopreserved PBMC and BMMC samples

Q² Solutions is the first and only service provider to achieve the exclusive certified service partnership for CITE-Seq scRNA-Seq with BioLegend. Describes CITE-Seq performance expectations for...

Brochure

Challenging Bioanalytical Work

If you’re looking for solutions to analytical challenges, you’ve come to the right place. Our highly trained scientists partner with you to provide a well-planned strategy, no matter where you are in...

Factsheet

CNS Biomarkers

Rules-Based Medicine, a Q² Solutions company, offers ultrasensitive immunoassays – including beta-amyloids, GFAP, NF-L, and pTaus – for the development of diagnostics and therapeutics for Alzheimer’s...